BioNTech (BNTX) Expected to Announce Quarterly Earnings on Monday

BioNTech (NASDAQ:BNTX - Get Free Report) is projected to announce its earnings results before the market opens on Monday, March 10th. Analysts expect the company to announce earnings of $0.38 per share and revenue of $1.24 billion for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.

BioNTech Stock Performance

Shares of BNTX traded down $2.05 during trading hours on Friday, reaching $108.78. 1,364,276 shares of the company traded hands, compared to its average volume of 781,154. The stock has a market capitalization of $26.08 billion, a P/E ratio of -51.80 and a beta of 0.30. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49. The business has a fifty day moving average price of $116.91 and a 200-day moving average price of $112.76.

Analysts Set New Price Targets

A number of research firms recently issued reports on BNTX. Canaccord Genuity Group boosted their target price on shares of BioNTech from $171.00 to $171.44 and gave the company a "buy" rating in a research report on Wednesday, November 27th. BMO Capital Markets restated an "outperform" rating on shares of BioNTech in a research report on Monday, December 2nd. Evercore ISI upgraded shares of BioNTech from an "in-line" rating to an "outperform" rating and boosted their target price for the company from $110.00 to $125.00 in a research report on Tuesday, November 19th. HC Wainwright restated a "buy" rating and set a $150.00 target price on shares of BioNTech in a research report on Monday, November 18th. Finally, Wells Fargo & Company began coverage on shares of BioNTech in a research report on Wednesday, December 11th. They set an "overweight" rating and a $170.00 target price for the company. Three analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $142.72.

Remove Ads

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.